Chemclin Diagnostics Co., Ltd. (SHA:688468)

Chemclin Diagnostics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	164.26	105.92	400.25	448.66	342.14	311.63
Short-Term Investments	118.09	207.97	-	-	-	-
Trading Asset Securities	231.53	301.22	509	470	643	613
Cash & Short-Term Investments	513.88	615.11	909.25	918.66	985.14	924.63
Cash Growth	-39.80%	-32.35%	-1.02%	-6.75%	6.54%	67.08%
Accounts Receivable	13.4	14.51	20.31	25.29	34.06	35.13
Other Receivables	15.23	18.92	25.1	6.48	2.94	3.21
Receivables	28.63	33.44	45.41	31.77	37.01	38.34
Inventory	108.27	110.05	109.26	110.61	112.56	122.36
Other Current Assets	5.3	2.99	3.76	41.59	30.55	5.96
Total Current Assets	656.08	761.59	1,068	1,103	1,165	1,091
Property, Plant & Equipment	454.81	467.2	483.65	495.01	223.44	157.85
Long-Term Investments	387.51	252.61	-	-	-	-
Goodwill	153.76	153.76	153.76	153.76	153.76	153.76
Other Intangible Assets	32.47	35.44	41.48	34.24	13.97	13.75
Long-Term Accounts Receivable	3.73	2.79	-	-	-	-
Long-Term Deferred Tax Assets	32.21	31.79	31.51	22.08	15.17	10.7
Long-Term Deferred Charges	47.14	48.73	54.08	12.84	19.59	3.55
Other Long-Term Assets	2.13	7.04	-	-	-	-
Total Assets	1,770	1,761	1,832	1,821	1,591	1,431

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	10.26	3.86	9.74	90.24	67.75	22.03
Accrued Expenses	10.69	13.27	19.4	22.22	38.88	24.13
Current Portion of Long-Term Debt	40.13	40.15	20.19	-	-	-
Current Portion of Leases	11.08	9.01	5.25	6.66	10.9	11.39
Current Income Taxes Payable	2.58	4.72	4.88	9.61	16.48	9.28
Current Unearned Revenue	14.24	13.06	9.6	6.91	4.58	3.57
Other Current Liabilities	68.57	75.48	114.29	58.5	58.67	51.16
Total Current Liabilities	157.55	159.54	183.35	194.13	197.25	121.56
Long-Term Debt	160.19	160.19	200.19	196.67	-	-
Long-Term Leases	18.44	22.62	24.12	31.28	1.57	13.22
Long-Term Unearned Revenue	2.66	2.75	-	-	-	5
Long-Term Deferred Tax Liabilities	4.56	4.95	8.18	9.68	11.77	12.46
Total Liabilities	343.4	350.05	415.85	431.76	210.59	152.23

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	401.11	401.11	401.11	401	401	401
Additional Paid-In Capital	565.66	565.66	565.66	564.92	564.92	547.48
Retained Earnings	510.75	495.22	500.63	422.88	414.65	330.2
Treasury Stock	-51.09	-51.09	-51.09	-	-	-
Shareholders' Equity	1,426	1,411	1,416	1,389	1,381	1,279
Total Liabilities & Equity	1,770	1,761	1,832	1,821	1,591	1,431

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	229.85	231.97	249.76	234.61	12.47	24.6
Net Cash (Debt)	284.03	383.14	659.5	684.05	972.67	900.03
Net Cash Growth	-52.26%	-41.90%	-3.59%	-29.67%	8.07%	62.64%
Net Cash Per Share	0.73	0.96	1.66	1.72	2.42	2.33
Filing Date Shares Outstanding	394.59	394.59	394.59	401	401	401
Total Common Shares Outstanding	394.59	394.59	394.59	401	401	401
Working Capital	498.53	602.05	884.33	908.49	968	969.74
Book Value Per Share	3.61	3.58	3.59	3.46	3.44	3.19
Tangible Book Value	1,240	1,222	1,221	1,201	1,213	1,111
Tangible Book Value Per Share	3.14	3.10	3.09	2.99	3.02	2.77
Buildings	306.04	306.04	306.04	-	-	-
Machinery	412.93	435.57	446.91	391.37	381.13	383.66
Construction In Progress	0.96	6.38	0.58	365.61	103.13	7.57

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 3, 2026

Data Sources Report a data error